カテゴリー： GlobalInfoResearch, 世界, 医療/バイオ

世界のインフルエンザ用ワクチン市場2022年：三価インフルエンザ用ワクチン、四価インフルエンザ用ワクチン

◆英語タイトル：Global Vaccine for Influenza Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

GlobalInfoResearchが発行した調査報告書（GIR22MY8982）◆商品コード：GIR22MY8982
◆発行会社（リサーチ会社）：GlobalInfoResearch
◆発行日：2022年5月（※2025年版があります。お問い合わせください。）
◆ページ数：91
◆レポート形式：英語 / PDF
◆納品方法：Eメール（注文後2-3日）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

インフルエンザ用ワクチン市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のインフルエンザ用ワクチンの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

インフルエンザ用ワクチン市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・三価インフルエンザ用ワクチン、四価インフルエンザ用ワクチン

用途別セグメントは次のように区分されます。
・子供向け（6ヶ月-3歳）、大人＆3歳以上子供向け

世界のインフルエンザ用ワクチン市場の主要な市場プレーヤーは以下のとおりです。
・Sanofi、CSL、GSK、Mylan、Hulan Bio、AstraZeneca、CCBIO

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、インフルエンザ用ワクチン製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なインフルエンザ用ワクチンメーカーの企業概要、2019年～2022年までのインフルエンザ用ワクチンの価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なインフルエンザ用ワクチンメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別インフルエンザ用ワクチンの販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのインフルエンザ用ワクチンの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのインフルエンザ用ワクチン市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびインフルエンザ用ワクチンの産業チェーンを掲載しています。
・第13、14、15章では、インフルエンザ用ワクチンの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Sanofi、CSL、GSK、Mylan、Hulan Bio、AstraZeneca、CCBIO
・メーカー別市場シェア
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：三価インフルエンザ用ワクチン、四価インフルエンザ用ワクチン
・用途別分析2017年-2028年：子供向け（6ヶ月-3歳）、大人＆3歳以上子供向け
・インフルエンザ用ワクチンの北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ
・インフルエンザ用ワクチンのヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア
・インフルエンザ用ワクチンのアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア
・インフルエンザ用ワクチンの南米市場規模2017年-2028年：ブラジル、アルゼンチン
・インフルエンザ用ワクチンの中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Vaccine for Influenza market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Vaccine for Influenza market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. For Children (6 months to 3 years) accounting for % of the Vaccine for Influenza global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Trivalent Influenza Vaccine segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Vaccine for Influenza include Sanofi, CSL, GSK, Mylan, and Hulan Bio, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Vaccine for Influenza market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
Market segment by Application can be divided into
For Children (6 months to 3 years)
For Adults and Children over 3 years
The key market players for global Vaccine for Influenza market are listed below:
Sanofi
CSL
GSK
Mylan
Hulan Bio
AstraZeneca
CCBIO
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Vaccine for Influenza product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Vaccine for Influenza, with price, sales, revenue and global market share of Vaccine for Influenza from 2019 to 2022.
Chapter 3, the Vaccine for Influenza competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Vaccine for Influenza breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Vaccine for Influenza market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Vaccine for Influenza.
Chapter 13, 14, and 15, to describe Vaccine for Influenza sales channel, distributors, customers, research findings and conclusion, appendix and data source.

❖ レポートの目次 ❖

1 Market Overview
1.1 Vaccine for Influenza Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Vaccine for Influenza Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Trivalent Influenza Vaccine
1.2.3 Quadrivalent Influenza Vaccine
1.3 Market Analysis by Application
1.3.1 Overview: Global Vaccine for Influenza Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 For Children (6 months to 3 years)
1.3.3 For Adults and Children over 3 years
1.4 Global Vaccine for Influenza Market Size & Forecast
1.4.1 Global Vaccine for Influenza Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Vaccine for Influenza Sales in Volume (2017-2028)
1.4.3 Global Vaccine for Influenza Price (2017-2028)
1.5 Global Vaccine for Influenza Production Capacity Analysis
1.5.1 Global Vaccine for Influenza Total Production Capacity (2017-2028)
1.5.2 Global Vaccine for Influenza Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Vaccine for Influenza Market Drivers
1.6.2 Vaccine for Influenza Market Restraints
1.6.3 Vaccine for Influenza Trends Analysis
2 Manufacturers Profiles
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Vaccine for Influenza Product and Services
2.1.4 Sanofi Vaccine for Influenza Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 CSL
2.2.1 CSL Details
2.2.2 CSL Major Business
2.2.3 CSL Vaccine for Influenza Product and Services
2.2.4 CSL Vaccine for Influenza Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business
2.3.3 GSK Vaccine for Influenza Product and Services
2.3.4 GSK Vaccine for Influenza Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Mylan
2.4.1 Mylan Details
2.4.2 Mylan Major Business
2.4.3 Mylan Vaccine for Influenza Product and Services
2.4.4 Mylan Vaccine for Influenza Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Hulan Bio
2.5.1 Hulan Bio Details
2.5.2 Hulan Bio Major Business
2.5.3 Hulan Bio Vaccine for Influenza Product and Services
2.5.4 Hulan Bio Vaccine for Influenza Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 AstraZeneca
2.6.1 AstraZeneca Details
2.6.2 AstraZeneca Major Business
2.6.3 AstraZeneca Vaccine for Influenza Product and Services
2.6.4 AstraZeneca Vaccine for Influenza Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 CCBIO
2.7.1 CCBIO Details
2.7.2 CCBIO Major Business
2.7.3 CCBIO Vaccine for Influenza Product and Services
2.7.4 CCBIO Vaccine for Influenza Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Vaccine for Influenza Breakdown Data by Manufacturer
3.1 Global Vaccine for Influenza Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Vaccine for Influenza Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Vaccine for Influenza
3.4 Market Concentration Rate
3.4.1 Top 3 Vaccine for Influenza Manufacturer Market Share in 2021
3.4.2 Top 6 Vaccine for Influenza Manufacturer Market Share in 2021
3.5 Global Vaccine for Influenza Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Vaccine for Influenza Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Vaccine for Influenza Market Size by Region
4.1.1 Global Vaccine for Influenza Sales in Volume by Region (2017-2028)
4.1.2 Global Vaccine for Influenza Revenue by Region (2017-2028)
4.2 North America Vaccine for Influenza Revenue (2017-2028)
4.3 Europe Vaccine for Influenza Revenue (2017-2028)
4.4 Asia-Pacific Vaccine for Influenza Revenue (2017-2028)
4.5 South America Vaccine for Influenza Revenue (2017-2028)
4.6 Middle East and Africa Vaccine for Influenza Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Vaccine for Influenza Sales in Volume by Type (2017-2028)
5.2 Global Vaccine for Influenza Revenue by Type (2017-2028)
5.3 Global Vaccine for Influenza Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Vaccine for Influenza Sales in Volume by Application (2017-2028)
6.2 Global Vaccine for Influenza Revenue by Application (2017-2028)
6.3 Global Vaccine for Influenza Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Vaccine for Influenza Sales by Type (2017-2028)
7.2 North America Vaccine for Influenza Sales by Application (2017-2028)
7.3 North America Vaccine for Influenza Market Size by Country
7.3.1 North America Vaccine for Influenza Sales in Volume by Country (2017-2028)
7.3.2 North America Vaccine for Influenza Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Vaccine for Influenza Sales by Type (2017-2028)
8.2 Europe Vaccine for Influenza Sales by Application (2017-2028)
8.3 Europe Vaccine for Influenza Market Size by Country
8.3.1 Europe Vaccine for Influenza Sales in Volume by Country (2017-2028)
8.3.2 Europe Vaccine for Influenza Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Vaccine for Influenza Sales by Type (2017-2028)
9.2 Asia-Pacific Vaccine for Influenza Sales by Application (2017-2028)
9.3 Asia-Pacific Vaccine for Influenza Market Size by Region
9.3.1 Asia-Pacific Vaccine for Influenza Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Vaccine for Influenza Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Vaccine for Influenza Sales by Type (2017-2028)
10.2 South America Vaccine for Influenza Sales by Application (2017-2028)
10.3 South America Vaccine for Influenza Market Size by Country
10.3.1 South America Vaccine for Influenza Sales in Volume by Country (2017-2028)
10.3.2 South America Vaccine for Influenza Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Vaccine for Influenza Sales by Type (2017-2028)
11.2 Middle East & Africa Vaccine for Influenza Sales by Application (2017-2028)
11.3 Middle East & Africa Vaccine for Influenza Market Size by Country
11.3.1 Middle East & Africa Vaccine for Influenza Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Vaccine for Influenza Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Vaccine for Influenza and Key Manufacturers
12.2 Manufacturing Costs Percentage of Vaccine for Influenza
12.3 Vaccine for Influenza Production Process
12.4 Vaccine for Influenza Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Vaccine for Influenza Typical Distributors
13.3 Vaccine for Influenza Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Vaccine for Influenza Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Vaccine for Influenza Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Sanofi Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi Major Business
Table 5. Sanofi Vaccine for Influenza Product and Services
Table 6. Sanofi Vaccine for Influenza Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. CSL Basic Information, Manufacturing Base and Competitors
Table 8. CSL Major Business
Table 9. CSL Vaccine for Influenza Product and Services
Table 10. CSL Vaccine for Influenza Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. GSK Basic Information, Manufacturing Base and Competitors
Table 12. GSK Major Business
Table 13. GSK Vaccine for Influenza Product and Services
Table 14. GSK Vaccine for Influenza Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Mylan Basic Information, Manufacturing Base and Competitors
Table 16. Mylan Major Business
Table 17. Mylan Vaccine for Influenza Product and Services
Table 18. Mylan Vaccine for Influenza Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Hulan Bio Basic Information, Manufacturing Base and Competitors
Table 20. Hulan Bio Major Business
Table 21. Hulan Bio Vaccine for Influenza Product and Services
Table 22. Hulan Bio Vaccine for Influenza Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 24. AstraZeneca Major Business
Table 25. AstraZeneca Vaccine for Influenza Product and Services
Table 26. AstraZeneca Vaccine for Influenza Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. CCBIO Basic Information, Manufacturing Base and Competitors
Table 28. CCBIO Major Business
Table 29. CCBIO Vaccine for Influenza Product and Services
Table 30. CCBIO Vaccine for Influenza Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Global Vaccine for Influenza Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 32. Global Vaccine for Influenza Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 33. Market Position of Manufacturers in Vaccine for Influenza, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 34. Global Vaccine for Influenza Production Capacity by Company, (K Units): 2020 VS 2021
Table 35. Head Office and Vaccine for Influenza Production Site of Key Manufacturer
Table 36. Vaccine for Influenza New Entrant and Capacity Expansion Plans
Table 37. Vaccine for Influenza Mergers & Acquisitions in the Past Five Years
Table 38. Global Vaccine for Influenza Sales by Region (2017-2022) & (K Units)
Table 39. Global Vaccine for Influenza Sales by Region (2023-2028) & (K Units)
Table 40. Global Vaccine for Influenza Revenue by Region (2017-2022) & (USD Million)
Table 41. Global Vaccine for Influenza Revenue by Region (2023-2028) & (USD Million)
Table 42. Global Vaccine for Influenza Sales by Type (2017-2022) & (K Units)
Table 43. Global Vaccine for Influenza Sales by Type (2023-2028) & (K Units)
Table 44. Global Vaccine for Influenza Revenue by Type (2017-2022) & (USD Million)
Table 45. Global Vaccine for Influenza Revenue by Type (2023-2028) & (USD Million)
Table 46. Global Vaccine for Influenza Price by Type (2017-2022) & (US$/Unit)
Table 47. Global Vaccine for Influenza Price by Type (2023-2028) & (US$/Unit)
Table 48. Global Vaccine for Influenza Sales by Application (2017-2022) & (K Units)
Table 49. Global Vaccine for Influenza Sales by Application (2023-2028) & (K Units)
Table 50. Global Vaccine for Influenza Revenue by Application (2017-2022) & (USD Million)
Table 51. Global Vaccine for Influenza Revenue by Application (2023-2028) & (USD Million)
Table 52. Global Vaccine for Influenza Price by Application (2017-2022) & (US$/Unit)
Table 53. Global Vaccine for Influenza Price by Application (2023-2028) & (US$/Unit)
Table 54. North America Vaccine for Influenza Sales by Country (2017-2022) & (K Units)
Table 55. North America Vaccine for Influenza Sales by Country (2023-2028) & (K Units)
Table 56. North America Vaccine for Influenza Revenue by Country (2017-2022) & (USD Million)
Table 57. North America Vaccine for Influenza Revenue by Country (2023-2028) & (USD Million)
Table 58. North America Vaccine for Influenza Sales by Type (2017-2022) & (K Units)
Table 59. North America Vaccine for Influenza Sales by Type (2023-2028) & (K Units)
Table 60. North America Vaccine for Influenza Sales by Application (2017-2022) & (K Units)
Table 61. North America Vaccine for Influenza Sales by Application (2023-2028) & (K Units)
Table 62. Europe Vaccine for Influenza Sales by Country (2017-2022) & (K Units)
Table 63. Europe Vaccine for Influenza Sales by Country (2023-2028) & (K Units)
Table 64. Europe Vaccine for Influenza Revenue by Country (2017-2022) & (USD Million)
Table 65. Europe Vaccine for Influenza Revenue by Country (2023-2028) & (USD Million)
Table 66. Europe Vaccine for Influenza Sales by Type (2017-2022) & (K Units)
Table 67. Europe Vaccine for Influenza Sales by Type (2023-2028) & (K Units)
Table 68. Europe Vaccine for Influenza Sales by Application (2017-2022) & (K Units)
Table 69. Europe Vaccine for Influenza Sales by Application (2023-2028) & (K Units)
Table 70. Asia-Pacific Vaccine for Influenza Sales by Region (2017-2022) & (K Units)
Table 71. Asia-Pacific Vaccine for Influenza Sales by Region (2023-2028) & (K Units)
Table 72. Asia-Pacific Vaccine for Influenza Revenue by Region (2017-2022) & (USD Million)
Table 73. Asia-Pacific Vaccine for Influenza Revenue by Region (2023-2028) & (USD Million)
Table 74. Asia-Pacific Vaccine for Influenza Sales by Type (2017-2022) & (K Units)
Table 75. Asia-Pacific Vaccine for Influenza Sales by Type (2023-2028) & (K Units)
Table 76. Asia-Pacific Vaccine for Influenza Sales by Application (2017-2022) & (K Units)
Table 77. Asia-Pacific Vaccine for Influenza Sales by Application (2023-2028) & (K Units)
Table 78. South America Vaccine for Influenza Sales by Country (2017-2022) & (K Units)
Table 79. South America Vaccine for Influenza Sales by Country (2023-2028) & (K Units)
Table 80. South America Vaccine for Influenza Revenue by Country (2017-2022) & (USD Million)
Table 81. South America Vaccine for Influenza Revenue by Country (2023-2028) & (USD Million)
Table 82. South America Vaccine for Influenza Sales by Type (2017-2022) & (K Units)
Table 83. South America Vaccine for Influenza Sales by Type (2023-2028) & (K Units)
Table 84. South America Vaccine for Influenza Sales by Application (2017-2022) & (K Units)
Table 85. South America Vaccine for Influenza Sales by Application (2023-2028) & (K Units)
Table 86. Middle East & Africa Vaccine for Influenza Sales by Region (2017-2022) & (K Units)
Table 87. Middle East & Africa Vaccine for Influenza Sales by Region (2023-2028) & (K Units)
Table 88. Middle East & Africa Vaccine for Influenza Revenue by Region (2017-2022) & (USD Million)
Table 89. Middle East & Africa Vaccine for Influenza Revenue by Region (2023-2028) & (USD Million)
Table 90. Middle East & Africa Vaccine for Influenza Sales by Type (2017-2022) & (K Units)
Table 91. Middle East & Africa Vaccine for Influenza Sales by Type (2023-2028) & (K Units)
Table 92. Middle East & Africa Vaccine for Influenza Sales by Application (2017-2022) & (K Units)
Table 93. Middle East & Africa Vaccine for Influenza Sales by Application (2023-2028) & (K Units)
Table 94. Vaccine for Influenza Raw Material
Table 95. Key Manufacturers of Vaccine for Influenza Raw Materials
Table 96. Direct Channel Pros & Cons
Table 97. Indirect Channel Pros & Cons
Table 98. Vaccine for Influenza Typical Distributors
Table 99. Vaccine for Influenza Typical Customers
List of Figures
Figure 1. Vaccine for Influenza Picture
Figure 2. Global Vaccine for Influenza Revenue Market Share by Type in 2021
Figure 3. Trivalent Influenza Vaccine
Figure 4. Quadrivalent Influenza Vaccine
Figure 5. Global Vaccine for Influenza Revenue Market Share by Application in 2021
Figure 6. For Children (6 months to 3 years)
Figure 7. For Adults and Children over 3 years
Figure 8. Global Vaccine for Influenza Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 9. Global Vaccine for Influenza Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Vaccine for Influenza Sales (2017-2028) & (K Units)
Figure 11. Global Vaccine for Influenza Price (2017-2028) & (US$/Unit)
Figure 12. Global Vaccine for Influenza Production Capacity (2017-2028) & (K Units)
Figure 13. Global Vaccine for Influenza Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Vaccine for Influenza Market Drivers
Figure 15. Vaccine for Influenza Market Restraints
Figure 16. Vaccine for Influenza Market Trends
Figure 17. Global Vaccine for Influenza Sales Market Share by Manufacturer in 2021
Figure 18. Global Vaccine for Influenza Revenue Market Share by Manufacturer in 2021
Figure 19. Vaccine for Influenza Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Vaccine for Influenza Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Vaccine for Influenza Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Vaccine for Influenza Sales Market Share by Region (2017-2028)
Figure 23. Global Vaccine for Influenza Revenue Market Share by Region (2017-2028)
Figure 24. North America Vaccine for Influenza Revenue (2017-2028) & (USD Million)
Figure 25. Europe Vaccine for Influenza Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Vaccine for Influenza Revenue (2017-2028) & (USD Million)
Figure 27. South America Vaccine for Influenza Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Vaccine for Influenza Revenue (2017-2028) & (USD Million)
Figure 29. Global Vaccine for Influenza Sales Market Share by Type (2017-2028)
Figure 30. Global Vaccine for Influenza Revenue Market Share by Type (2017-2028)
Figure 31. Global Vaccine for Influenza Price by Type (2017-2028) & (US$/Unit)
Figure 32. Global Vaccine for Influenza Sales Market Share by Application (2017-2028)
Figure 33. Global Vaccine for Influenza Revenue Market Share by Application (2017-2028)
Figure 34. Global Vaccine for Influenza Price by Application (2017-2028) & (US$/Unit)
Figure 35. North America Vaccine for Influenza Sales Market Share by Type (2017-2028)
Figure 36. North America Vaccine for Influenza Sales Market Share by Application (2017-2028)
Figure 37. North America Vaccine for Influenza Sales Market Share by Country (2017-2028)
Figure 38. North America Vaccine for Influenza Revenue Market Share by Country (2017-2028)
Figure 39. United States Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Vaccine for Influenza Sales Market Share by Type (2017-2028)
Figure 43. Europe Vaccine for Influenza Sales Market Share by Application (2017-2028)
Figure 44. Europe Vaccine for Influenza Sales Market Share by Country (2017-2028)
Figure 45. Europe Vaccine for Influenza Revenue Market Share by Country (2017-2028)
Figure 46. Germany Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Vaccine for Influenza Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Vaccine for Influenza Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Vaccine for Influenza Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Vaccine for Influenza Revenue Market Share by Region (2017-2028)
Figure 55. China Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Vaccine for Influenza Sales Market Share by Type (2017-2028)
Figure 62. South America Vaccine for Influenza Sales Market Share by Application (2017-2028)
Figure 63. South America Vaccine for Influenza Sales Market Share by Country (2017-2028)
Figure 64. South America Vaccine for Influenza Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Vaccine for Influenza Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Vaccine for Influenza Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Vaccine for Influenza Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Vaccine for Influenza Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Vaccine for Influenza Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Vaccine for Influenza in 2021
Figure 76. Manufacturing Process Analysis of Vaccine for Influenza
Figure 77. Vaccine for Influenza Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界のインフルエンザ用ワクチン市場2022年：三価インフルエンザ用ワクチン、四価インフルエンザ用ワクチン(Global Vaccine for Influenza Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 再集合体鳥インフルエンザウイルスワクチンのグローバル市場予測2023-2029
  • 世界のインフルエンザワクチン注射市場インサイト及び予測（三価インフルエンザワクチン、四価インフルエンザワクチン）
  • 世界の犬用インフルエンザワクチン市場2022年：液体、粉体
  • 世界の馬インフルエンザワクチン市場2022年：液体、粉末
  • 世界のインフルエンザNA阻害剤市場2022年：ザナミビル、オセルタミビル、ペラミビル